在前列腺癌患者接受荷尔蒙治疗时,Oxybutynin减少热闪烁,提高睡眠和生活质量,并尽可能减少副作用。 Oxybutynin reduced hot flashes in prostate cancer patients on hormone therapy, improving sleep and quality of life with minimal side effects.

由Mayo诊所牵头的第二阶段试验发现,催产素是一种通常用于过活性膀胱的药物,它大大减少了接受前列腺癌激素治疗的男子的热闪烁。 A Mayo Clinic-led phase 2 trial found that oxybutynin, a drug typically used for overactive bladder, significantly reduced hot flashes in men undergoing hormone therapy for prostate cancer. 在88名参与者中,与安慰剂相比,接受较高剂量者平均每天的热闪电量比安慰剂少近7次,75%以上的参与者报告严重程度至少降低50%。 Among 88 participants, those on a higher dose averaged nearly seven fewer hot flashes per day compared to placebo, with over 75% reporting at least a 50% reduction in severity. 与会者还经历了睡眠、日常运作和生活质量的改善,没有严重的副作用;干口是最常见的不利影响。 Participants also experienced improved sleep, daily functioning, and quality of life, with no serious side effects; dry mouth was the most common adverse effect. 这项研究是肿瘤学临床试验联盟的一部分,它支持将催产素作为管理这种共同治疗副作用的一个安全有效的选择,尽管需要进行更大的试验来确认结果和确定最佳剂量。 The study, part of the Alliance for Clinical Trials in Oncology, supports oxybutynin as a safe and effective option for managing this common treatment side effect, though larger trials are needed to confirm results and determine optimal dosing.